The present disclosure relates to a thrombin antibody, an antigen-binding fragment and the pharmaceutical use thereof. Furthermore, the present disclosure relates to a murine antibody, a chimeric antibody and a humanized antibody comprising the CDR region of the thrombin antibody, and a pharmaceutical composition comprising the thrombin antibody and/or the antigen-binding fragment thereof, as well as the use thereof as a drug. In particular, the present disclosure relates to thr use of the humanized thrombin antibody in preparing a drug for treating thrombin-related diseases or conditions.